We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » CanSino’s Late-Stage COVID-19 Vaccine Trial Enrolls Over 20,000
CanSino’s Late-Stage COVID-19 Vaccine Trial Enrolls Over 20,000
CanSino Biologics has enrolled more than 20,000 participants in a global phase 3 study of its COVID-19 vaccine candidate, Ad5-nCoV, co-developed with a research arm of the Chinese military.